Numerous studies have explored the potential of targeting the HIF1 signaling pathway in cancer treatment, particularly targeting a core HIF1 downstream molecule, vascular endothelial growth factor (VEGF) [4, 11–13]. This evidence concerns the gene HIF1A and cancer.